Nicole Sweeny Sells 3,975 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the completion of the transaction, the insider owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This represents a 7.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

KalVista Pharmaceuticals Trading Down 0.1%

Shares of KalVista Pharmaceuticals stock opened at $15.76 on Thursday. The company’s 50-day moving average price is $15.49 and its 200-day moving average price is $13.95. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.23 and a 12-month high of $19.00. The company has a market cap of $796.67 million, a price-to-earnings ratio of -3.99 and a beta of -0.19.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. HC Wainwright raised their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Needham & Company LLC boosted their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its position in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $55,000. Wolverine Asset Management LLC purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $57,000. KLP Kapitalforvaltning AS purchased a new position in shares of KalVista Pharmaceuticals in the third quarter valued at about $63,000. Finally, Truvestments Capital LLC raised its stake in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.